The past six months have been a windfall for Biogen’s shareholders. The company’s stock price has jumped 41.7%, setting a new ...

Shares of Biogen Inc. slipped 5.04% to $169.31 Wednesday, on what proved to be an all-around grim trading session for the ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...

Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8. Truist lifted the price target on the stock to ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, ...

Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials for Q2 2025, thanks mainly to a strong uptake for its Alzheimer’s therapy ...

Florida-based J. L. Bainbridge sold 119,376 shares of Biogen for an estimated $16.1 million in the third quarter. After the transaction, J. L. Bainbridge reported holding just 2,969 shares of Biogen ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Biogen Inc. closed 2.40% short of its 52-week high of $190.20, which the company reached on January 9th.